Compare ASPS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASPS | TIL |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.0M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | ASPS | TIL |
|---|---|---|
| Price | $6.09 | $7.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 26.4K | ★ 269.3K |
| Earning Date | 03-12-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $169,648,000.00 | N/A |
| Revenue This Year | $38.29 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $899.06 | ★ N/A |
| Revenue Growth | ★ 10.68 | N/A |
| 52 Week Low | $4.92 | $5.67 |
| 52 Week High | $15.96 | $42.79 |
| Indicator | ASPS | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 31.70 |
| Support Level | $5.55 | $6.79 |
| Resistance Level | $6.06 | $7.29 |
| Average True Range (ATR) | 0.42 | 0.34 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 39.66 | 55.12 |
Altisource Portfolio Solutions SA is an integrated service provider and marketplace for the real estate and mortgage industries. It operates via two reportable segments, namely Servicer and Real Estate, which derive maximum revenue, and Origination. The Servicer and Real Estate segment provides loan servicers and real estate investors with solutions and technologies that span the mortgage and real estate lifecycle. The Origination segment provides originators with solutions and technologies that span the mortgage origination lifecycle. Altisource mainly serves financial institutions, government-sponsored enterprises, and originators in the United States, with the majority of its revenue flowing from field services and mortgage and real estate solutions.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.